The multi-year program, which will award a total of up to $3 million in grants to investigators in the United States, is an extension of Pfizer’s Advancing Science through Pfizer Investigator Research Exchange initiative.
Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results...
Pfizer Inc. today announced that it has received a request for additional information from the...
The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.
This video showcases the precision engineering involved when GEA Pharma Systems, G-CON and Pfizer collaborated to develop modular, next generation processing technologies for oral solid dosage forms. The technology was recognized at last week's INTERPHEX with an Exhibitor Award.
Pfizer overcame patent expirations to beat Wall Street projections for the first quarter, though it cut its outlook for the year.
Pfizer said that an experimental blood cancer drug met one of its two goals in a late-stage trial, as patients who were treated with the drug were more likely to have a complete remission.
Pfizer, Inc. is supporting research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease.
The company that manufactures the birth control medication Alesse is giving Shoppers Drug Mart credit for alerting the public that expired pills had been dispensed in the last few weeks.
A commonly prescribed antidepressant caused up to a six-fold increase in atherosclerosis plaque in the coronary arteries of non-human primates.
Viagra and other related drugs are not a universal 'cure-all' for impotence, according to a new study from The University of Manchester.
Pfizer has stopped selling its Prevnar 7 pneumonia vaccine in China after its import license expired, but the U.S. drugmaker still intends to launch the world's most widely used vaccine, Prevnar 13, in that market.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.
The National Advertising Division--an industry regulatory agency administered by the Council of Better Business Bureaus--investigated Prestige Brands Holdings' Little Remedies products following a complaint by Pfizer.
Pfizer has announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica® (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia (FM).
Pfizer has announced that the European Commission approved an expanded indication for the use of Prevenar 13 for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older.
The accelerated stock buyback is part of its $11B share repurchase plan authorized in October. It said it will receive the approximately 150 million shares involved in the buyback from Goldman Sachs on Wednesday.
The Hospira deal will add significant value to Pfizer’s GEP segment, a vertical which has been rumored to be sold or spun-off as a separate entity. This somewhat mirrors Pfizer’s strategic objective to focus on core growth platforms in the branded drug market while divesting its ancillary operations, similar to when it carved-out its Animal Health business and brought it public.
Pfizer is buying Hospira for approximately $15.23 billion, saying it is a good fit with its established global pharmaceutical business. The buyout will also help Pfizer tap into the growing market for biosimilars, which are cheaper versions of biologic drugs that are used to treat conditions such as anemia.
Pfizer anounced the FDA has granted accelerated approval of IBRANCE®, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Pfizer's fourth-quarter profit fell by half as worsening generic competition and unfavorable currency rates reduced sales, and higher research spending and legal costs also hurt the bottom line. The world's second-biggest drugmaker by revenue reported lower sales for most of its huge portfolio of prescription medicines, with the biggest hit coming from new generic competition to popular painkiller Celebrex.
Pfizer on Tuesday reported fourth-quarter earnings of $1.23B. On a per-share basis, the company said it had net income of 19 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 54 cents per share.
The first in a new class of cancer medicines, Pfizer's Ibrance, appears poised for approval to treat advanced breast cancer within just a few months and could quickly become a blockbuster, some analysts believe.
Pfizer has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate.
Pfizer has announced top-line results from a double-blind Phase III study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherapeutic neuralgia (pain after shingles or PHN).
Pfizer has announced enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
Under the terms of the agreement, OPKO will receive an upfront payment of $295M and is eligible to receive up to an additional $275M upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide.
- Page 1